share_log

Humanigen's Anti-Tumor Ifabotuzumab Notches Positive Phase 1 Results

Dow Jones Newswires ·  Apr 9, 2021 19:27

DJ Humanigen's Anti-Tumor Ifabotuzumab Notches Positive Phase 1 Results

By Matt Grossman

Humanigen Inc.'s ifabotuzumab drug achieved positive results in a Phase 1 safety and bio-imaging trial in patients with glioblatoma multiforme, the company said Friday.

Glioblatoma multiforme is a type of brain cancer.

At both doses in the study, ifabotuzumab showed sensitive and specific tumor targeting in all the patients who received it, Humanigen said. The adverse events in the study were readily manageable, the company said.

Andrew Scott, the study's principal investigator, said the results support further investigation of the drug's effect on other solid tumors in a Phase 2 study.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

April 09, 2021 07:27 ET (11:27 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment